RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
  • Regulatory NewsRegulatory News

    Democrats, Republicans Prep to Take Up Drug Prices Together

    Following the House’s transition Tuesday to a Democratic majority, Senate Majority Leader Mitch McConnell (R-KY) said Wednesday that he will work with House Democrats on crafting a plan to tackle high prescription drug prices.   “I can’t imagine that won’t be on the agenda,” McConnell said regarding prescription drug prices. Potential House speaker Nancy Pelosi (D-CA) also further indicated that representatives and senators on both sides of the aisle will look to find ...
  • Regulatory NewsRegulatory News

    European Regulatory Roundup: UK Hurries Drug Pricing Bill Ahead of Election (4 May 2017)

    Welcome to our European Regulatory Roundup, our weekly overview of the top EU regulatory news. UK Hurries Through Drug Pricing Bill Before Parliament Closes for Snap Election Politicians in the UK have hurried through drug pricing legislation before Parliament closed ahead of a snap general election. The calling of the surprise election created a deadline for resolving a dispute between the two houses of the UK Parliament, prompting politicians to create a compr...
  • Regulatory NewsRegulatory News

    EMA Re-Elects Former MHRA Regulator to Lead Influential Management Board

    The European Medicines Agency (EMA) has announced the re-election of Sir Kent Woods as the chair of its influential 35-member Management Board, which sets regulatory policies for the agency. Woods, who served as chief executive at the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) between 2004 and 2013 , will now serve as the board's chair for a final three-year term, after which time term limits preclude him from running again. Woods said in ...
  • Report: User Fees Could Be In Peril in Partisan Congress

    A Bloomberg Government study claims a partisan Congress seeking to make changes to the US Food and Drug Administration (FDA) and the user fee legislation that funds it could put the entire package of user fee legislation in jeopardy. The pieces of user fee legislation currently before Congress included the Prescription Drug User Fee Act (PDUFA), the Medical Device User Fee Act (MDUFA), the Generic Drugs User Fee Act (GDUFA), and the Biosimilar and Interchangeab...